Menu Search
Equities

Neuca SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NEU:WSE

Neuca SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)775.00
  • Today's Change6.00 / 0.78%
  • Shares traded833.00
  • 1 Year change-5.49%
  • Beta0.6149
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Neuca SA is a Poland-based company, which operates in the healthcare market. The Company is mainly involved in the distribution of drugs to pharmacies. It also operates in other sectors of the health market, such as production of drugs, supplements and cosmetics under its own brand, clinical trials, telemedicine, Information Technology (IT) solutions and e-commerce in the health care industry.

  • Revenue in PLN (TTM)13.34bn
  • Net income in PLN153.80m
  • Incorporated2001
  • Employees5.19k
  • Location
    Neuca SAul. Forteczna 35-37TORUN 87-100PolandPOL
  • Phone+48 566694000
  • Fax+48 566694111
  • Websitehttps://www.neuca.pl/
More ▼

Institutional shareholders

9.47%Per cent of shares held by top holders
HolderShares% Held
Allianz Polska PTE SAas of 31 Dec 2024170.35k3.69%
TFI PZU SAas of 30 Jun 202547.66k1.03%
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 202545.26k0.98%
Allianz Polska TFI SAas of 30 Jun 202540.16k0.87%
Norges Bank Investment Managementas of 30 Jun 202538.90k0.84%
PKO TFI SAas of 30 Dec 202534.84k0.75%
Vienna PTE SA Vienna Insurance Groupas of 31 Dec 202423.95k0.52%
Dimensional Fund Advisors LPas of 05 Feb 202616.62k0.36%
Investors TFI SAas of 30 Jun 202511.23k0.24%
Pekao TFI SAas of 30 Jun 20258.61k0.19%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.